Skip to main content

Aptensio XR

(methylphenidate hydrochloride)

Aptensio XR (methylphenidate hydrochloride); CII

Full Prescribing Information DailyMed Drug Information

Summary

Aptensio XR is a long-acting methylphenidate CNS stimulant supplied as a multilayer-bead extended-release capsule, approved for ADHD from age 6 with no upper age limit. Each bead carries an immediate-release layer over a controlled-release layer, producing two plasma peaks from one morning dose. The capsule may be opened and sprinkled on applesauce, which is its practical advantage over a swallow-whole osmotic tablet. Schedule II; brand and generic.

Forms & Strengths

  • Extended-release capsules (multilayer beads, may be opened onto applesauce): 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg

Dosing

  • Age: >= 6y; no upper limit
  • Onset: ~ 1 hour
  • Duration: up to 12 hours
  • Release Profile: 40% IR / 60% ER via multilayer beads
  • Initial Dose: 10 mg once daily in the morning
  • Titration: 10 mg every 7 days
  • Max Dose: 60 mg/day
  • Considerations: May be swallowed whole or opened onto applesauce, but never divided, so the ladder moves in whole capsules only.

Pharmacology

  • Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
  • Delivery / Release: 40% IR / 60% ER via multilayer beads. Initial peak at about 2 hours, a dip over 4 to 6 hours, then a second peak at about 8 hours.
  • Metabolism: De-esterified to ritalinic acid, inactive. No CYP pathway. Terminal half-life about 5.1 hours; ~90% recovered in urine, so renal impairment has little effect.
  • Class Positioning: Racemic, unlike dexmethylphenidate products. Against Concerta it trades an ascending profile for two peaks and can be opened; not interchangeable with Metadate CD or Ritalin LA.
  • Alcohol: at 40% alcohol, 96% of the dose released within two hours in vitro. Dose dumping is a real risk in an adolescent who drinks.

Indications

  • ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients ≥ 6 y/o

Off-Label Uses

  • Narcolepsy (ICD-10: G47.411, G47.419): IR methylphenidate carries this indication, Aptensio XR does not. Extrapolates from the moiety, not the product; limited data.
  • ADHD in children 4 to under 6 years (ICD-10: F90.x): the label records evidence against. 50% (20 of 39) dropped 10 or more weight percentiles, on exposure 2 to 3 fold higher. Benefits do not outweigh risks.
  • Treatment-resistant depression augmentation (ICD-10: F32.x, F33.x): adult literature only; insufficient in children.
  • Cognitive enhancement in youth without ADHD: not an indication and not supported.

Contraindications & Warnings

  • Boxed Warning: Abuse, misuse and addiction, with overdose and death; risk rises with dose and non-oral routes. Assess abuse risk before prescribing and reassess throughout treatment.
  • Contraindicated:
    • Hypersensitivity to methylphenidate; angioedema and anaphylaxis reported
    • MAOI use, current or within 14 days: hypertensive crisis
  • Use with caution:
    • Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid
    • Pre-existing hypertension: mean rises 2 to 4 mmHg and 3 to 6 bpm, individually larger
    • Psychotic or bipolar disorder: exacerbation and treatment-emergent mania
    • Personal or family history of tics or Tourette's syndrome
    • Significant hyperopia or angle-closure risk: refer to ophthalmology
    • Substance use disorder in patient or household
  • Screen before starting:
    • Cardiac history and exam, plus family history of sudden death; mandatory in section 2.1
    • Tics or Tourette's, personal and family, with clinical evaluation; also mandatory
    • Risk factors for a manic episode: depressive symptoms, family history of bipolar disorder or suicide
    • Abuse and diversion risk in patient and household
    • Baseline height, weight, blood pressure and heart rate

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days.
  • Antihypertensives: effectiveness reduced. Increase BP monitoring and adjust the antihypertensive.
  • Halogenated anesthetics (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold on the day of surgery.
  • Risperidone: EPS may increase when either dose changes in either direction. Monitor across any titration.
  • Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only. Counsel on symptoms rather than avoiding.
  • Alcohol: a formulation interaction, not a pharmacologic one; 96% released within two hours at 40% alcohol. Counsel adolescents explicitly.

Administration

  • Once daily in the morning. The label asks for a consistent routine with meals rather than fed or fasted.
  • Swallow whole, or sprinkle the entire contents onto applesauce and eat at once without chewing. Never store a sprinkled dose.
  • Never divide a capsule. Sprinkling is a swallowing accommodation, not a way to split a dose.
  • A high-fat meal blunts or removes the second peak and raises Cmax ~28%. An erratic breakfast makes the afternoon erratic.
  • Missed dose: give the next as scheduled. Never double up or give a first dose late in the day.
  • Store locked; dispose of unused capsules through a take-back program.

Side Effects

  • Common, pediatric 6 to 17 y (vs placebo): headache 10.9% vs 8.5%, insomnia 9.8% vs 2.1%, upper abdominal pain 8.2% vs 0%, decreased appetite 4.9% vs 0%, nausea 3.8%, vomiting 3.8%.
  • Serious:
    • Sudden death with structural cardiac disease: avoid the drug rather than monitor through it
    • New psychosis or mania, ~0.1% pooled, including with no psychiatric history: consider discontinuing
    • Priapism, sometimes surgical, typically after a dose increase and also during drug holidays
    • Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit
    • Growth suppression: about 2 cm and 2.7 kg less over 3 years
    • Acute angle closure glaucoma; new or worsening tics and Tourette's: discontinue if appropriate
    • Hypersensitivity including angioedema and anaphylaxis
    • Postmarketing: severe hepatic injury, serotonin syndrome, seizures including grand mal, rhabdomyolysis, pancytopenia

Monitoring & Labs

  • Cardiovascular: BP and HR at baseline, at each dose change, and every 6 months.
  • Growth: height, weight and BMI at baseline and every 6 months. Crossing two percentile lines is a labeled trigger to interrupt.
  • Appetite and sleep: at every visit; both are dose-timing problems before they are drug problems.
  • Psychiatric and tics: screen for psychosis, mania, aggression and tics at every visit and after each dose increase.
  • Digital perfusion: inspect fingers and toes at each visit for colour change or ulceration.
  • Ocular: no routine schedule; refer before starting in significant hyperopia, and at any new eye pain or halos.
  • Abuse and diversion: at every refill, capsule count, ask about sharing and selling, check the PDMP. A boxed-warning obligation.
  • Laboratory: none required. Check LFTs only for jaundice, dark urine or unexplained fatigue.
  • Efficacy stopping rule: discontinue if no improvement after appropriate dose adjustment over one month. A labeled instruction.

Discontinuation & Taper

  • Can be stopped abruptly at therapeutic doses; the label gives no taper schedule.
  • Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite. Do not read it as relapse.
  • Reduce or discontinue for paradoxical worsening or adverse reactions.
  • Drug holidays are reasonable where growth limits treatment. Priapism has been reported during holidays and on discontinuation.

Pregnancy & Lactation

  • Pregnancy: human data are limited and insufficient to inform a drug-associated risk. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%. Weigh against untreated maternal ADHD.
  • Lactation: infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case. Monitor for agitation, poor feeding and reduced weight gain. Not a reason to stop breastfeeding. (LactMed 2025)
  • Lactation, milk supply: prolactin falls; large doses may interfere before supply is established. (LactMed 2025)
  • Exposure Registry: National Pregnancy Registry for Psychostimulants, 1-866-961-2388.

Counseling Points

  • Counsel the family on:

    • The two-peak profile: a mid-morning dip, then coverage to about 12 hours. Unwarned families read the dip as too low a dose.
    • Sprinkling onto applesauce, eaten straight away without chewing, never saved for later.
    • Never splitting a capsule; the ladder moves in whole capsules only.
    • Keeping breakfast consistent; a fatty breakfast on some days and none on others changes the afternoon.
    • Moving the largest meal to breakfast and the evening, since appetite suppression peaks midday.
    • Locked storage; sharing or selling a Schedule II medication is a felony.
    • For adolescents, that alcohol can release almost the whole capsule at once. Specific to this formulation.

  • Advise them to call for:

    • Chest pain, fainting, or a racing heart that does not settle.
    • New hallucinations, or new suspicious or fearful thinking.
    • Numbness, coldness, or colour change in the fingers or toes.
    • A new or markedly worse tic, or a new vocal tic.
    • Weight loss, or clothes fitting more loosely over a few weeks.
    • A painful erection lasting more than a few hours, which is a surgical emergency.
    • Yellowing of the eyes or skin, dark urine, or new eye pain with halos around lights.

References

  1. DailyMed. Aptensio XR (methylphenidate hydrochloride) extended-release capsules prescribing information. Rhodes Pharmaceuticals LLC. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66
  2. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/
  3. FDA. openFDA National Drug Code Directory, methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22methylphenidate%22
  4. AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/
  5. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
  6. DEA. Drug scheduling. Methylphenidate is a Schedule II controlled substance. https://www.dea.gov/drug-information/drug-scheduling
Back to top